Abstract Objective To study the association of Nod-like receptor protein 3 (NLRP3) inflammasome with inflammatory response in the acute stage and coronary artery lesion (CAL) in children with Kawasaki disease (KD). Methods A total of 42 children with KD who were hospitalized from January to October 2017 were enrolled as the KD group, among whom 9 had CAL (CAL group) and 33 had no CAL (NCAL group). Fifteen age-and gendermatched children with pneumonia and pyrexia were enrolled as the pneumonia-pyrexia group. Fifteen healthy children were enrolled as the healthy control group. Real-time PCR was used to measure the mRNA expression of NLRP3 inflammasome (NLRP3, ASC and caspase-1) in peripheral blood mononuclear cells. The Spearman rank correlation test was used to investigate the correlation of NLRP3 mRNA expression with serum levels of C-reactive protein, erythrocyte sedimentation rate, interleukin-6, interleukin-1β, procalcitonin, albumin and prealbumin. Results The KD group had significantly higher mRNA expression of NLRP3, ASC and caspase-1 in the acute stage than the pneumonia-pyrexia and healthy control groups (P < 0.05). The CAL group had significantly higher mRNA expression of NLRP3 than the NCAL group (P < 0.05). NLRP3 mRNA expression was correlated with C-reactive protein, interleukin-6, interleukin-1β, and prealbumin levels in children with KD in the acute stage (rs=0.449, 0.376, 0.427, and -0.416 respectively; P < 0.05). Conclusions NLRP3 inflammasome may participate in inflammatory response in the acute stage and the development of CAL in children with KD.
LIU Li-Ping,YUAN Yong-Hua,HE Xue-Hua et al. Expression of Nod-like receptor protein 3 inflammasome in peripheral blood mononuclear cells of children with Kawasaki disease in the acute stage[J]. CJCP, 2019, 21(10): 992-997.
LIU Li-Ping,YUAN Yong-Hua,HE Xue-Hua et al. Expression of Nod-like receptor protein 3 inflammasome in peripheral blood mononuclear cells of children with Kawasaki disease in the acute stage[J]. CJCP, 2019, 21(10): 992-997.
Newburger JW, Takahashi M, Burns JC. Kawasaki disease[J]. J Am Coll Cardiol, 2016, 67(14):1738-1749.
[2]
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease:a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17):e927-e999.
Kim KY, Kim DS. Recent advances in Kawasaki disease[J]. Yonsei Med J, 2016, 57(1):15-21.
[5]
Hoang LT, Shimizu C, Ling L, et al. Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease[J]. Genome Med, 2014, 6(11):541.
[6]
Masters SL, Simon A, Aksentijevich I, et al. Horror autoinflammaticus:the molecular pathophysiology of autoinflammatory disease[J]. Annu Rev Immunol, 2009, 27:621-668.
[7]
Chen Y, Li X, Boini KM, et al. Endothelial Nlrp3 inflammasome activation associated with lysosomal destabilization during coronary arteritis[J]. Biochim Biophys Acta, 2015, 1853(2):396-408.
[8]
Pouillon V, Hascakova-Bartova R, Pajak B, et al. Inositol 1,3,4,5-tetrakisphosphate is essential for T lymphocyte development[J]. Nat Immunol, 2003, 4(11):1136-1143.
Ozaki E, Campbell M, Doyle SL. Targeting the NLRP3 inflammasome in chronic inflammatory diseases:current perspectives[J]. J Inflamm Res, 2015, 8:15-27.
[11]
Dusser P, Koné-Paut I. IL-1 inhibition may have an important role in treating refractory Kawasaki disease[J]. Front Pharmacol, 2017, 8:163.
[12]
Liu Q, Zhang D, Hu D, et al. The role of mitochondria in NLRP3 inflammasome activation[J]. Mol Immunol, 2018, 103:115-124.
[13]
Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death[J]. Immunol Rev, 2011, 243(1):206-214.
[14]
Mariathasan S, Newton K, Monack DM, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf[J]. Nature, 2004, 430(6996):213-218.
[15]
Gross O, Thomas CJ, Guarda G, et al. The inflammasome:an integrated view[J]. Imuunol Rev, 2011, 243(1):136-151.
[16]
de Torre-Minguela C, Mesa Del Castillo P, Pelegrín P. The NLRP3 and pyrin inflammasomes:implications in the pathophysiology of autoinflammatory diseases[J]. Front Immunol, 2017, 8:43.
[17]
Choulaki C, Papadaki G, Repa A, et al. Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis[J]. Arthritis Res Ther, 2015, 17:257.
[18]
Liu X, Shen J, Fan D, et al. Yupingfeng San inhibits NLRP3 inflammasome to attenuat the inflammatory response in asthma mice[J]. Front Pharmacol, 2017, 8:944.
[19]
Zaki MH, Boyd KL, Vogel P, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis[J]. Immunity, 2010, 32(3):379-391.
[20]
Alphonse MP, Duong TT, Shumitzu C, et al. Inositoltriphosphate 3-kinase C mediates inflammasome activation and treatment response in Kawasaki disease[J]. J Immunol, 2016, 197(9):3481-3489.
Barranco C. Vasculitis syndromes:Kawasaki disease is IL-1β-mediated[J]. Nat Rev Rheumatol, 2016, 12(12):693.
[23]
Wakita D, Kurashima Y, Crother TR, et al. Role of interleukin-1 signaling in a mouse model of Kawasaki disease-associated abdominal aortic aneurysm[J]. Arterioscler Thromb Vasc Biol, 2016, 36(5):886-897.
[24]
Song XY, Huang JY, Hong Q, et al. Platelet count and erythrocyte sedimentation rate are good predictors of Kawasaki disease:ROC analysis[J]. J Clin Lab Anal, 2010, 24(6):385-388.
